The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma (Q36870585)

16 August 2017

1 reference

title

The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma (English)

1 reference

16 August 2017

Athanasios Dimopoulos

series ordinal

2

object named as

Dimopoulos MA

1 reference

16 August 2017

Terpos E

1

1 reference

PubMed ID

17611556

16 August 2017

Sezer O

series ordinal

3

1 reference

16 August 2017

5 July 2007

1 reference

16 August 2017

1 reference

16 August 2017

21

1 reference

16 August 2017

9

1 reference

16 August 2017

1875-1884

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.leu.2404843

16 August 2017

0 references

cites work

Bisphosphonates: clinical experience

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

Myeloma bone disease: pathophysiology and management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

Biochemical markers of bone metabolism in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

Thalidomide and CC-5013 in multiple myeloma: the University of Arkansas experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

RANK ligand and osteoprotegerin in myeloma bone disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

Transforming growth factor-beta increases interleukin-6 transcripts in osteoblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

Treatment for myeloma bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

Aetiology of bone disease and the role of bisphosphonates in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish co-operative study group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

Zoledronic Acid and renal toxicity: data from French adverse effect reporting database

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

Thalidomide and lenalidomide in the treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

Thalidomide and hematopoietic-cell transplantation for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

Bortezomib inhibits human osteoclastogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

E3 Ubiquitin Ligase Smurf1 Mediates Core-binding Factor α1/Runx2 Degradation and Plays A Specific Role in Osteoblast Differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

High serum bone-specific alkaline phosphatase level after bortezomib-combined therapy in refractory multiple myeloma: possible role of bortezomib on osteoblast differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

Autologous stem cell transplantation normalizes abnormal bone remodeling and sRANKL/osteoprotegerin ratio in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

Two histone deacetylase inhibitors, trichostatin A and sodium butyrate, suppress differentiation into osteoclasts but not into macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

Inhibition of histone deacetylase suppresses osteoclastogenesis and bone destruction by inducing IFN-beta production

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-?B ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

7 January 2021

Expression of interleukin-1beta and tumour necrosis factor-alpha in plasma cells from patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

7 January 2021

Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

7 January 2021

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

7 January 2021

Impaired osteoblastogenesis in myeloma bone disease: role of upregulated apoptosis by cytokines and malignant plasma cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

7 January 2021

Upregulation of osteoblast apoptosis by malignant plasma cells: a role in myeloma bone disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

7 January 2021

Anti-myeloma activity of pamidronate in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

7 January 2021

The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

7 January 2021

Effect of daily etidronate on the osteolysis of multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

7 January 2021

Subgroup and cost-benefit analysis of the Finnish multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

7 January 2021

A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

7 January 2021

Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

7 January 2021

Scleritis complicating zoledronic acid infusion

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

7 January 2021

Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

7 January 2021

Primary surgical therapy for osteonecrosis of the jaw secondary to bisphosphonate therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

7 January 2021

Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

7 January 2021

Use of bisphosphonates in multiple myeloma: IMWG response to Mayo Clinic consensus statement

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

7 January 2021

Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

7 January 2021

The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

7 January 2021

Response to bortezomib and activation of osteoblasts in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

7 January 2021

Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404843

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2404843

1 reference

PubMed ID

17611556

Dimensions Publication ID

16 August 2017

0 references

1 reference

PubMed ID

17611556